Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Regeneron Pharmaceuticals, Inc. (REGN:NASDAQ), powered by AI.

Current Price
$614.73
P/E Ratio
14.3
Market Cap
64.3B
Sector
Healthcare
What is the Regeneron Pharmaceuticals, Inc. stock price forecast?

Regeneron Pharmaceuticals, Inc. is currently trading at $614.73. View real-time AI analysis on Alpha Lenz.

What is Regeneron Pharmaceuticals, Inc. insider trading activity?

View the latest insider trading data for Regeneron Pharmaceuticals, Inc. on Alpha Lenz.

What is Regeneron Pharmaceuticals, Inc.'s P/E ratio?

Regeneron Pharmaceuticals, Inc.'s P/E ratio is 14.3.

Regeneron Pharmaceuticals, Inc.

NASDAQ · REGN
$614.73-0.25(-0.04%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Regeneron Pharmaceuticals, Inc.'s future dividend policy...
Alpha Chat Insight

Regeneron Pharmaceuticals, Inc. trades at a P/E of 14.3 (undervalued) with solid ROE of 14.9%. Operating margin of 25.8% indicates strong profitability.

Ask for details

Company Overview

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, manufacturing, and commercialization of innovative medicines that address serious medical conditions. The company is recognized for its robust research platforms, particularly in the fields of immunology, oncology, and rare diseases. By leveraging advanced genetic and molecular technologies, Regeneron develops therapies targeting a broad spectrum of diseases worldwide, including ophthalmic, cardiovascular, and infectious conditions. Its portfolio includes several blockbuster biologic drugs, further underscoring its scientific leadership in monoclonal antibodies and gene therapy. Regeneron plays a pivotal role in the global healthcare sector, providing treatments that improve patient outcomes and collaborating with external partners to advance new therapeutic options. The company’s strong financial performance, with substantial revenues and consistent profitability, highlights its significant presence and influence within the biotech industry, driving both medical innovation and market growth.

CEODr. Leonard S. Schleifer M.D., Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees15,182

Company Statistics

FY 2025

Profile

$64.30BMarket Cap
$14.34BRevenue
0.00Shares Out
15,182Employees

Margins

85.35%Gross
34.83%EBITDA
25.81%Operating
36.47%Pre-Tax
31.41%Net

Valuation

14.27P/E
2.06P/B
4.48EV/Sales
12.79EV/EBITDA
17.08P/FCF

Growth (CAGR)

5.62%Rev 3Yr
11.04%Rev 5Yr
-9.50%Op Inc 3Yr
0.69%Op Inc 5Yr
1.26%Net Inc 3Yr
5.10%Net Inc 5Yr

Returns

11.50%ROA
14.87%ROE
13.47%ROIC

Financial Health

$3.12BCash & Cash Equivalents
$6.18BNet Debt
29.76%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Regeneron Pharmaceuticals, Inc. (ticker: REGN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 15,182 employees. Market cap is $64.3B.

The current price is $614.73 with a P/E ratio of 14.27x and P/B of 2.06x.

ROE is 14.87% and operating margin is 25.81%. Annual revenue is $14.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecast 2026 $614.73 — Price, Financials & Analyst Targets | Alpha Lenz